Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NRX PHARMACEUTICALS, INC.

(NRXP)
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

NRX Pharmaceuticals Soars After Saying Zyesami Outperformed Remdesivir for Critical COVID-19 Patients

11/29/2021 | 02:48pm EST


ę MT Newswires 2021
All news about NRX PHARMACEUTICALS, INC.
01:19aRelief Therapeutics Partner NRX Expands US Access to COVID-19 Treatment Zyesami
MT
01/18NRX Pharmaceuticals Secures Expansion of Zyesami in Expanded Access, Right to Try Progr..
MT
01/18NRx Pharmaceuticals Announces Expansion of ZYESAMI« (aviptadil) US Expanded Access and ..
AQ
01/14NRx Responds to Relief's Allegations of January 14, 2022
GL
01/14Relief Therapeutics Responds To NRx Lawsuit Claims; Shares Down 10%
MT
01/13GLOBAL MARKETS LIVE : Tesco, Google, Microsoft, Adler, TPG...
01/13NRX Pharmaceuticals Sues Relief Therapeutics for Alleged Breach of COVID-19 Drug Collab..
MT
01/11NRX Pharmaceuticals Plans Study of COVID-19 Booster Vaccine Against Omicron
MT
01/11NRx Announces Planned Study Investigating BriLife™ Booster Vaccine Against Omicro..
GL
01/11NRx Announces Planned Study Investigating BriLife™ Booster Vaccine Against Omicro..
GL
More news
Financials (USD)
Sales 2020 - - -
Net income 2020 -51,8 M - -
Net cash 2020 1,06 M - -
P/E ratio 2020 -5,11x
Yield 2020 -
Capitalization 235 M 235 M -
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees -
Free-Float 40,6%
Chart NRX PHARMACEUTICALS, INC.
Duration : Period :
NRx Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NRX PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
Jonathan C. Javitt Chairman & Chief Executive Officer
James Brandon Chief Financial Officer
Robert Besthof Chief Commercial & Patent Officer, Head-Operations
Patrick J. Flynn Independent Director
Daniel E. Troy Independent Director
Sector and Competitors
1st jan.Capi. (M$)
NRX PHARMACEUTICALS, INC.-16.32%235
MODERNA, INC.-26.53%75 661
LONZA GROUP AG-15.05%52 427
IQVIA HOLDINGS INC.-14.11%46 293
SEAGEN INC.-15.72%23 824
ICON PUBLIC LIMITED COMPANY-17.86%20 707